Deltex Medical Group PLC Issue of Equity (1909G)
22 Julio 2021 - 09:48AM
UK Regulatory
TIDMDEMG
RNS Number : 1909G
Deltex Medical Group PLC
22 July 2021
22 July 2021
Deltex Medical Group plc
Issue of equity to satisfy outstanding equity-settled
non-executive directors' fees
Deltex Medical Group plc (the "Group" or "Deltex Medical") (AIM:
DEMG), the global leader in oesophageal Doppler monitoring, further
to the announcement made on 16 July 2021, today announces the issue
of 1,371,429 ordinary shares (the "New Shares") at the price of
1.75 pence per New Share to satisfy deferred non-executive
directors' fees for Sir Duncan Nichol, who retired from his
position on the board as a director as of 31 December 2020. This
will be the final equity settled non-executive directors' fees
payment to Sir Duncan Nichol. Further detail is given below.
Outstanding equity-settled non-executive directors' fees
Further to the announcement issued by the Group on 21 December
2020, the New Shares are being issued to the Non-Executive
Directors and the Chairman of the Group to satisfy outstanding fees
owed to them. The New Shares will be issued at 1.75 pence per New
Share, representing the closing mid-market price on 21 July
2021.
Details of the New Shares to be issued to the retired Deltex
Medical director are set out in the table below.
Ex-Director Current % New Shares Post transaction %
shares held holding
Sir Duncan
Nichol 8,788,663 1.51 1,371,429 10,160,092 1.74
------------- ----- ----------- ----------------- -----
Admission
Application has been made to the London Stock Exchange for the
New Shares to be admitted to trading on AIM. It is expected that
admission will take place and dealings in the New Shares will
commence on AIM on or around 8.00 a.m. on 28 July 2021.
Total voting rights
Immediately following admission, the Company's issued share
capital will be 584,943,796 ordinary shares of 1 pence each
("Ordinary Shares"). Deltex Medical does not hold any Ordinary
Shares in treasury. The total voting rights figure, immediately
following admission of the New Shares, of 584,943,796 may be used
by shareholders (and others with notification obligations) as the
denominator for the calculations by which they will determine
whether they are required to notify their interest in, or a change
to their interest in, Deltex Medical under the FCA's Disclosure
Guidance and Transparency Rules.
For further information, please contact:
Deltex Medical Group plc 01243 774 837
Nigel Keen, Chairman investorinfo@Deltexmedical.com
Andy Mears, Chief Executive
Natalie Wettler, Group Finance Director
Arden Partners plc 020 7614 5900
Paul Shackleton info@arden-partners.com
Oscair McGrath
Joint Broker
Turner Pope Investments (TPI) Ltd 0203 657 0050
Andy Thacker info@turnerpope.com
James Pope
Notes for Editors
Deltex Medical manufactures and markets haemodynamic monitoring
technologies which are primarily used in critical care and general
surgical procedures. Deltex Medical's proprietary oesophageal
Doppler monitoring ("ODM") (TrueVue Doppler) measures blood flow
velocity in the central circulation in real time. Minimally
invasive, easy to set-up and quick to focus, the technology
generates a low-frequency ultrasound signal which is highly
sensitive to changes in blood flow and measures such changes in
'real time'. Deltex Medical is the only company in the enhanced
haemodynamic monitoring space to have built a robust and credible
evidence base demonstrating both the clinical and economic benefits
of its core technology: TrueVue Doppler. This technology has been
proven in a wide range of clinical trials to reduce complications
suffered by patients after surgery and consequently can save
hospitals money.
Deltex Medical's TrueVue System on the CardioQ-ODM+ monitor
platform now provides clinicians with two further advanced
haemodynamic monitoring technologies. TrueVue Impedance is an
entirely non-invasive monitoring technology which transmits low
magnitude, high frequency electrical signals through the thorax and
measures the changes to this signal when the heart pumps blood.
TrueVue PressureWave uses the peripheral blood pressure signal
analysis to give doctors information on changes in the circulation
and is particularly suited to monitoring lower risk or
haemodynamically stable patients.
Group goal
Haemodynamic management is now becoming widely accepted as a
vital part of the anaesthesia protocols for surgical patients, as
well as treating ventilated intensive care patients, including
ventilated COVID-19 patients. Consequently, the Group's focus is on
maximising value from the opportunities associated with: the CV-19
pandemic; the elective surgery backlog; and the higher profile of
haemodynamic monitoring which has arisen from the recent
consolidation in the sector. The Group aims to provide clinicians
with a modern, next generation, single 'haemodynamic workstation'
platform which offers them a range of technologies from simple to
sophisticated to be deployed according to the patient's clinical
condition as well as the skill and expertise of the user. Doing
this will enable the Group to partner with healthcare providers to
support modern haemodynamic management across the whole
hospital.
The Group is currently in the implementation phase of achieving
this goal in a number of territories worldwide, operating directly
in the UK and the USA, and via agreements with approximately 40
distributors overseas.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOESEMFLEEFSELW
(END) Dow Jones Newswires
July 22, 2021 10:48 ET (14:48 GMT)
Deltex Medical (LSE:DEMG)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Deltex Medical (LSE:DEMG)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024